{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:06:07Z","timestamp":1791302767810,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.autrev.2010.06.006","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T09:24:00Z","timestamp":1277371440000},"page":"761-770","source":"Crossref","is-referenced-by-count":21,"title":["Pulmonary arterial hypertension in systemic sclerosis"],"prefix":"10.1016","volume":"9","author":[{"given":"Sevdalina","family":"Lambova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2010.06.006_bib1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association.","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J AmColl Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2003.11.004","article-title":"Pulmonary hypertension in autoimmune rheumatic diseases","volume":"3","author":"Carreira","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.06.006_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestationsin systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condiffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1445-5994.2007.01370.x","article-title":"Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment","volume":"37","author":"Proudman","year":"2007","journal-title":"Int Med J"},{"key":"10.1016\/j.autrev.2010.06.006_bib6","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.cpm.0000197403.64631.de","article-title":"Collagen vascular diseases of the lung","volume":"13","author":"Frankel","year":"2006","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib8","first-page":"1292","article-title":"Pulmonary hypertension in a lupus clinic: experience with twenty-four patients","volume":"17","author":"Asherson","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/39.12.1320","article-title":"Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients","volume":"39","author":"Dawson","year":"2000","journal-title":"Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib10","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/art.10442","article-title":"Pulmonary hypertension in autoimmune rheumatic diseases. Where are we now?","volume":"46","author":"Magliano","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/ard.57.11.682","article-title":"Mortality and causes of death in a Swedish series of systemic sclerosis patients","volume":"57","author":"Hesselstrand","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib12","series-title":"Arthritis and allied conditions","first-page":"1633","article-title":"Systemic sclerosis and scleroderma variants: clinical aspects","author":"Silver","year":"2005"},{"key":"10.1016\/j.autrev.2010.06.006_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/pcad.2002.130041","article-title":"Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension","volume":"45","author":"Jeffery","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib14","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J AmColl Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.trsl.2007.12.010","article-title":"Identification of candidate genes in scleroderma-related pulmonary arterial hypertension","volume":"151","author":"Grigoryev","year":"2008","journal-title":"Transl Res"},{"key":"10.1016\/j.autrev.2010.06.006_bib16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.54.9.730","article-title":"Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension","volume":"54","author":"Morelli","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.06-0682","article-title":"Endothelin-1\/endothelin-3 ratio \u2014 a potential prognostic factor of pulmonary arterial hypertension","volume":"131","author":"Montani","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2010.06.006_bib20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patiens with primary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib21","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/art.11060","article-title":"Increased asymmetric dimethylarginine and endothelin-1 levels in secondary Raynaud's phenomenon","volume":"48","author":"Rajagopalan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00002281-200211000-00010","article-title":"Targeting mediators of vascular injury in scleroderma","volume":"14","author":"Schachna","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib23","first-page":"11","article-title":"A review of pulmonary arterial hypertension: role of ambrisentan","volume":"3","author":"Barst","year":"2007","journal-title":"Vasc H\u0435alth Risk Manag"},{"key":"10.1016\/j.autrev.2010.06.006_bib24","first-page":"752","article-title":"Understanding, assessing and treating Raynaud's phenomenon","volume":"17","author":"Boin","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib25","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/art.10895","article-title":"Endothelin and endothelin receptor antagonists in systemic rheumatic diseases","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib26","doi-asserted-by":"crossref","first-page":"v25","DOI":"10.1093\/rheumatology\/ken283","article-title":"Endothelin and scleroderma lung disease","volume":"47","author":"Silver","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.06.006_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/bdrc.10030","article-title":"Biology of platelet-derived growth factors in development","volume":"69","author":"Betsholtz","year":"2003","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.autrev.2010.06.006_bib28","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","article-title":"Role of PDGF in fibrotic disease and systemic sclerosis","volume":"47","author":"Trojanowska","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.06.006_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4065\/81.9.1241","article-title":"Biology of platelet-derived growth factor and its involvement in disease","volume":"81","author":"Alvarez","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2010.06.006_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2466-9-18","article-title":"Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis","volume":"9","author":"Papaioannou","year":"2009","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J Pathol"},{"issue":"Suppl","key":"10.1016\/j.autrev.2010.06.006_bib32","first-page":"59","article-title":"N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis","volume":"27","author":"Allanore","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib33","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary hypertension in patients with systemic sclerosis and effects of calcium channel blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib34","doi-asserted-by":"crossref","first-page":"v36","DOI":"10.1093\/rheumatology\/ken270","article-title":"Biomarkers in systemic sclerosis","volume":"47","author":"Doran","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.06.006_bib35","first-page":"353","article-title":"Increased serum soluble CD40 levels in patients with systemic sclerosis","volume":"34","author":"Komura","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/ard.2003.020040","article-title":"Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers","volume":"64","author":"Allanore","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib37","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","article-title":"Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon","volume":"336","author":"Bunker","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2010.06.006_bib38","doi-asserted-by":"crossref","first-page":"H681","DOI":"10.1152\/ajpheart.1992.263.3.H681","article-title":"CGRP and somatostatin modulate chronic pulmonary hypertension","volume":"263","author":"Tjen-A-Looi","year":"1992","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/j.autrev.2010.06.006_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/ard.61.3.261","article-title":"Correlation between plasma concentrations of pressure in patients with systemic sclerosis calcitonin gene related peptide and pulmonary","volume":"61","author":"Bartosik","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0889-857X(21)00216-7","article-title":"Sensory neuropeptides and rheumatic disease","volume":"19","author":"Matucci-Cerinic","year":"1993","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2010.06.006_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2007.01497.x","article-title":"Pulmonary hypertension and the serotonin hypothesis: where are we now?","volume":"61","author":"MacLean","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.autrev.2010.06.006_bib42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cvr\/cvp306","article-title":"In vivo effects of a combined 5-HT1B receptor\/SERT antagonist in experimental pulmonary hypertension","volume":"85","author":"Morecroft","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2010.06.006_bib43","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.08-2823","article-title":"Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension","volume":"136","author":"Shah","year":"2009","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.autrev.2010.06.006_bib44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2010.06.006_bib45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.33549\/physiolres.930238","article-title":"Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia","volume":"51","author":"Novotn\u00e1","year":"2002","journal-title":"Physiol Res"},{"key":"10.1016\/j.autrev.2010.06.006_bib46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1183\/09031936.03.00038903","article-title":"Inflammation in pulmonary hypertension","volume":"22","author":"Dorfm\u00fcller","year":"2003","journal-title":"Eur Respir J"},{"issue":"Suppl I","key":"10.1016\/j.autrev.2010.06.006_bib47","first-page":"I1","article-title":"Recommen- dations on the management of pulmonary hypertension in medical practice","volume":"86","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.autrev.2010.06.006_bib48","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/ers.09.5","article-title":"Therapies for scleroderma-related pulmonary arterial hypertension","volume":"3","author":"Hassoun","year":"2009","journal-title":"Exp Rev Resp Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.healun.2009.07.005","article-title":"Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension","volume":"29","author":"Chandra","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.autrev.2010.06.006_bib51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of Iiolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib52","first-page":"458","article-title":"Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization","volume":"35","author":"Hsu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib53","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.22696","article-title":"Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis\u2013 associated interstitial lung disease are not predictive of disease progression","volume":"56","author":"Goh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2007.087353","article-title":"Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis","volume":"68","author":"Hofstee","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib55","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.1780280505","article-title":"Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis","volume":"28","author":"Lovy","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib56","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0735-1097(00)00994-3","article-title":"Inhaled nitric oxide selectively dilated pulmonary vasculature in adult patients with pulmonary hypertensionq irrespective of etiology","volume":"36","author":"Krasuski","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib57","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0735-1097(98)00361-1","article-title":"Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine","volume":"32","author":"Ricciardi","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib58","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/BOR.0b013e3283307dc8","article-title":"Therapy for pulmonary arterial hypertension associated with systemic sclerosis","volume":"21","author":"Mathai","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib59","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2010.06.006_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2010.06.006_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib62","doi-asserted-by":"crossref","first-page":"452-434","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2010.06.006_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2010.06.006_bib64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/PL00011223","article-title":"Clinical systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years","volume":"21","author":"Bettoni","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib65","doi-asserted-by":"crossref","first-page":"339-3","DOI":"10.1183\/09031936.02.02462001","article-title":"Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension","volume":"20","author":"Hoeper","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2010.06.006_bib66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-6980(01)00131-9","article-title":"Novel mode of action of iloprost: in vitro downregulation of endothelial cell adhesion molecules","volume":"65","author":"Della","year":"2001","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.autrev.2010.06.006_bib67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/00015550152572976","article-title":"Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels","volume":"81","author":"Mittag","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2010.06.006_bib68","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib69","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2007.09.031","article-title":"Short- and long- term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension","volume":"51","author":"Ivy","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.autrev.2010.06.006_bib71","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebocontrolled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.autrev.2010.06.006_bib72","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9149(96)90408-7","article-title":"Short term hemodinamic effect of a new oral PgI2 analogue, Beraprost, in pulmonary and secondary pulmonary hypertension","volume":"78","author":"Saji","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib73","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al. Digital ulcers in systemic sclerosis prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib75","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2010.06.006_bib76","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib77","first-page":"151","article-title":"A review of sitaxsentan sodium in patients with pulmonary arterial hypertension","volume":"3","author":"Waxman","year":"2007","journal-title":"Vasc H\u0435alth Risk Manag"},{"issue":"3","key":"10.1016\/j.autrev.2010.06.006_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1527-3466.2006.00063.x","article-title":"Ambrisentan, a non-peptide endothelin receptor antagonist","volume":"24","author":"Vatter","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"issue":"7","key":"10.1016\/j.autrev.2010.06.006_bib80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.autrev.2010.02.012","article-title":"Phosphodiesterase inhibitors in the management of autoimmune disease","volume":"9","author":"Shenoy","year":"2010","journal-title":"Autoimmune Rev"},{"key":"10.1016\/j.autrev.2010.06.006_bib81","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib82","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc053442","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"354","author":"Hoeper","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib83","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2230.2005.01797.x","article-title":"Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis","volume":"30","author":"Kamata","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib84","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/ard.2003.015677","article-title":"Severe digital ischaemia treated with phosphodiesterase inhibitors","volume":"63","author":"Kumana","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.06.006_bib85","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-139-10-200311180-00030","article-title":"Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and Raynaud's phenomenon","volume":"139","author":"Rosenkranz","year":"2003","journal-title":"Ann Int Med"},{"key":"10.1016\/j.autrev.2010.06.006_bib86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.mvr.2005.03.001","article-title":"Use of tadalafil in patient with secondary Raynaud's phenomenon not responding to sildenafil","volume":"69","author":"Baumhaekel","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.autrev.2010.06.006_bib87","first-page":"1488-75","article-title":"Differences in hemodynamic and oxygenation responses to three different phoshodiesterase-5 inhibitors in patients with pulmonary arterial hypertension","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib88","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1093\/rheumatology\/ken276","article-title":"Intracellular tyrosine kinase as a novel targets for anti-fibrotic therapy in systemic sclerosis","volume":"47","author":"Distler","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.06.006_bib89","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal 1037of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2010.06.006_bib90","unstructured":"Beyer C, Distler JHW, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?"},{"key":"10.1016\/j.autrev.2010.06.006_bib91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2008.06.082","article-title":"Statins supress MMP2 secretion via inactivation Rho\/ROCK pathway in pulmonary vascular smooth muscles cells","volume":"591","author":"Li","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2010.06.006_bib92","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension","volume":"49","author":"Wang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.autrev.2010.06.006_bib93","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients","volume":"35","author":"Koh","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2010.06.006_bib94","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.06.006_bib95","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmune Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T20:14:21Z","timestamp":1711570461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997210001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1568997210001242"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2010.06.006","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}